Enhanced efficacy CAR T-cell therapies

DE602016095621T2Active Publication Date: 2026-06-17NOVARTIS AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
NOVARTIS AG
Filing Date
2016-09-16
Publication Date
2026-06-17

AI Technical Summary

Technical Problem

Existing CAR T cell therapies lack efficacy in treating hematologic cancers and other diseases associated with tumor antigens.

Method used

Engineering T cells to express a chimeric antigen receptor (CAR) with inhibitors of Tet1, Tet2, and/or Tet3, such as siRNA, shRNA, or gene editing systems, to disrupt these genes and reduce their expression or function, thereby enhancing CAR T cell proliferation and function.

Benefits of technology

The disruption of Tet1, Tet2, and/or Tet3 leads to decreased 5-hydroxymethylcytosine levels, improving CAR T cell proliferation and cytokine production, resulting in enhanced therapeutic efficacy against tumor antigens.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.